TABLE 5.
Prediction accuracy of LogitDA with the adjusted cutoffs of the ten drugs.
| Drug (resource) | n a | Cutoff | Prediction accuracy | False positive rate | False negative rate |
|---|---|---|---|---|---|
| Docetaxel (GSE6434) | 24 | 0.73 | 0.62 | 0.36 | 0.40 (4/10) |
| Erlotinib (GSE33072) | 25 | 0.09 | 0.76 | 0.00 | 0.55 (6/11) |
| Sorafenib (GSE33072) | 37 | 0.24 | 0.62 | 0.63 b | 0.19 (4/21) |
| Cetuximab (PDX) | 60 | 0.34 | 0.93 | 0.00 | 0.80 (4/5) |
| Erlotinib (PDX) | 21 | 0.33 | 0.86 | 0.00 | 1.00 (3/3) |
| Gemcitabine (PDX) | 25 | 0.90 | 0.72 | 0.06 | 0.86 (6/7) |
| Paclitaxel (PDX) | 43 | 0.95 | 0.88 | 0.00 | 1.00 (5/5) |
| Cisplatin (TCGA) | 66 | 0.05 | 0.88 | 0.83 b | 0.05 (3/60) |
| Docetaxel (TCGA) | 16 | 0.66 | 0.69 | 0.38 | 0.25 (2/8) |
| Gemcitabine (TCGA) | 57 | 0.86 | 0.70 | 0.17 | 0.52 (11/21) |
a
n denotes the sample size.
b
The false positive rate of sorafenib (GSE33072) and cisplatin (TCGA) are 10/16 and 5/6, respectively.